Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Valneva SE (VALN) Q2 2026 Earnings Call Transcript
Valneva Q2 Earnings Call Highlights
Valneva NASDAQ: VALN reported lower first-half revenue and wider losses for 2026, while maintaining its full-year sales outlook and emphasizing its cash position, restructuring measures and expectations for regulatory progress on its Lyme disease vaccine candidate with Pfizer.
Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript
Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript
Valneva Q1 Earnings Call Highlights
Valneva NASDAQ: VALN reported lower first-quarter revenue and a wider loss for 2026, while management said the company is focused on conserving cash as it awaits the next regulatory steps for its Lyme disease vaccine candidate being developed with Pfizer.
VALN Stock Nosedives on Mixed Results From Lyme Disease Vaccine Study
Valneva plunges 37% as Lyme vaccine study shows 70%+ efficacy but misses key statistical target, raising concerns despite plans for regulatory filings.
Valneva (VALN) Soars 17.4%: Is Further Upside Left in the Stock?
Valneva (VALN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
VALN Doses First Infant With Shigella Vaccine in Mid-Stage Study
Valneva intends to test its experimental Shigella vaccine in nearly 110 infants. Results from this study are expected later this year.
Favorable VLA1553-321 Phase 3 Study Results Boost VALN Stock
Valneva reports positive data from its Phase 3 - VLA1553-321 study of the IXCHIQ vaccine.
Chikungunya Vaccine Label Extension Call Likely to Support VALN Stock
The FDA application complements recent label extension submissions to the EMA and Health Canada, highlighting Valneva's strategic push to enhance IXCHIQ's global reach.
Favorable VLA15 Phase 2 Study Results Might Boost VALN Stock
Valneva and Pfizer report positive immunogenicity and safety data from their Phase 2 study of the VLA15 vaccine. Phase 3 trials for VLA15 are in progress.
Wall Street Analysts Predict a 150.41% Upside in Valneva (VALN): Here's What You Should Know
The consensus price target hints at a 150.4% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
How Much Upside is Left in Valneva (VALN)? Wall Street Analysts Think 135.3%
The consensus price target hints at a 135.3% upside potential for Valneva (VALN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
